Overview

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Status:
Recruiting

Trial end date:
2025-07-24

Target enrollment:

Participant gender:

Summary

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Kartos Therapeutics, Inc.

Collaborator:

Telios Pharma, Inc.